MedTrace Logo

Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model for Breast Cancer Leptomeningeal Metastasis

NCT07386886 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403

Last updated 2026-02-04

No results posted yet for this study

Summary

The investigators conducted a large, multicenter retrospective study of patients with breast cancer leptomeningeal metastasis (BCLM), constituting one of the largest and most comprehensively curated cohorts to date. Data from 403 patients diagnosed between November 2013 and November 2025 were collected from three major academic centers. Detailed clinical, pathological, diagnostic, and treatment data were analyzed. Overall survival (OS) was evaluated, and independent prognostic factors were identified via Cox regression. A novel Breast Cancer Leptomeningeal Graded Prognostic Assessment (BC-LGPA) model was developed and validated for risk stratification.

Conditions

  • Leptomeningeal Metastasis in Breast Cancer

Interventions

DRUG

systematic therapy

Patients with BCLM receive systematic therapy，IT and radiation.

Sponsors & Collaborators

  • Jian Zhang,MD

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2025-11-30
Completion
2026-01-26

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07386886 on ClinicalTrials.gov